课题基金 / 基金详情

Molecular Mediators and Regulators of Glucocorticoid Act

Molecular Mediators and Regulators of Glucocorticoid Act
糖皮质激素作用的分子介质和调节剂
批准号:
6993547
负责人:
Tomoshige Kino
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至

项目摘要

项目成果

Tomoshige Kino的其他基金

相似基金

相关文献

中文摘要
翻译
糖皮质激素具有广泛的生命维持功能,在多种炎症性/自身免疫性/过敏性和淋巴增生性疾病的治疗中发挥重要作用。组织对糖皮质激素反应性的改变可能会产生病理状态,并影响疾病的病程和对治疗的反应。我们研究了家族性/散发性糖皮质激素抵抗综合征的病理生理机制,该综合征是由糖皮质激素受体(GR)基因突变引起的。我们通过检测病理性突变体受体GRV571A、GRD641V、GRV729I、GRGRI559N和GRI747M的核穿梭、DNA结合活性、与p160共激活子的相互作用和对野生型受体的转显性负活性,分析了它们的功能缺陷,并比较了所观察到的突变体?缺陷与患者的临床表型。我们还发现了一个新的病理杂合子突变,该突变将GR的773位氨基酸的亮氨酸替换为Pro。该突变体由于不能在其配体结合区形成配体依赖的反式激活表面而表现出较低的反式激活活性,表现为正常受体的显性负抑制,从而在杂合性条件下产生临床病理。 为了发现影响组织对糖皮质激素敏感性的细胞内分子,我们进行了酵母双杂交筛选。GR特异性地结合了孤儿核受体之一,鸡卵清蛋白上游启动子转录因子II(COUP-TFII)。GR和COUP-TFII在参与中间代谢的几个基因启动子上相互影响转录活性。我们还发现G蛋白偶联受体下游的介体鸟嘌呤核苷酸结合蛋白(G蛋白)β和转化生长因子β/骨形态发生蛋白诱导的Smad6抑制因子与GR特异地相互作用。Gbeta和Smad6蛋白均抑制GR诱导的糖皮质激素反应启动子的反式激活。与Dogma相反,前者与其伴侣分子G-γ一起,在糖皮质激素的作用下与GR共同迁移到细胞核,并被位于糖皮质激素反应基因启动子区域的糖皮质激素反应元件(GRE)所吸引。这些结果表明,G蛋白β/γ复合体可能通过干扰GR调节启动子上的GR相关转录体来抑制GR的转录活性。相反,Smad6通过吸引组蛋白去乙酰基酶来抑制GR的转录活性,其功能类似于其他经典分子,如核受体核心抑制物(NCoR)和视黄醇和甲状腺激素受体的沉默介体(SMRT)。除上述蛋白外,我们还发现自身免疫调节蛋白(AIRE)与GR相互作用并增强其转录活性。AIRE的突变导致自身免疫性多内分泌病-外胚层营养不良综合征(APECED)。AIRE有四个LxxLL特征基序,经典的核受体共激活子通过这些基序与配体激活的受体分子相互作用。AIRE中这些基序的破坏干扰了它与GR的相互作用,并使其对GR反式激活的增强作用失活,表明AIRE可能通过使用这些特征基序作为GR的组织特异性(胸腺)共激活因子。我们还在研究BRX,一种Rho类型的鸟嘌呤核苷酸交换因子,它通过将Rho家族的小G蛋白从非活性的GDP结合形式转换为活性的GTP结合形式来激活它们。该蛋白在其C-末端有一个核受体相互作用结构域。我们已经证明了BRX通过激活和紧密吸引小G蛋白到GR来增强GR的转录活性。内源性BRX是糖皮质激素在脾淋巴细胞中发挥作用所必需的,并介导溶血磷脂酸(LPA)诱导的GR反式激活的增强。 我们正在研究GRbeta和转录辅助激活因子TRAP220在调节组织对糖皮质激素敏感性方面的作用。前者是经典受体GRpha的剪接变体,而后者是巨大的辅助激活蛋白复合体Drop/Trap的组成部分。我们建立了稳定高表达GFP-GRβ的细胞系,并从R.Roeder?S博士的实验室获得了TRAP220KO细胞。我们正在使用常规的DNA微阵列芯片来检测它们的表达/缺失对糖皮质激素诱导的转录活性的影响。为了阐明将GR吸引到其启动子区域的内源基因,我们开发了CpG微阵列芯片,其中包括10,000多个内源基因的启动子区域。我们使用GR抗体进行染色质免疫沉淀分析,并将用收获的DNA处理芯片,以发现吸引GR的内源性启动子。 由人类免疫缺陷病毒1型(HIV-1)感染引起的获得性免疫缺陷综合征(AIDS)患者有几种临床表现,与组织对糖皮质激素敏感性的增加相适应。我们重点研究了HIV-1编码的辅助蛋白之一VPR,并证明了这种病毒多肽作为GR的辅助调节因子。我们进一步研究了VPR诱导GR反式激活共激活的机制,重点研究了它与宿主核受体辅活化子p300/CBP的相互作用,并通过检测VPR辅活化子活性对糖皮质激素反应性白细胞介素12和其他基因产物的产生/分泌的影响,探讨了VPR辅活化子活性的生物学意义。我们的发现可以解释艾滋病的几种表现,包括与T辅助细胞1/T辅助细胞2转移相关的免疫抑制,肌病,肌肉无力/萎缩,以及肥胖相关的胰岛素抵抗伴代谢和心血管症状。
英文摘要
Glucocorticoids have a broad array of life-sustaining functions and play important roles in the therapy of several inflammatory/autoimmune/allergic and lymphoproliferative disorders. Changes of tissue responsiveness to glucocorticoids may produce pathologic states and influence both the course of a disease and its response to therapy. We investigated the pathophysiologic mechanisms of the familial/sporadic glucocorticoid resistance syndrome, which is caused by mutations of the glucocorticoid receptor (GR) gene. We analyzed the functional defects of pathologic mutant receptors GRV571A, GRD641V, GRV729I, GRGRI559N and GRI747M by examining their nuclear shuttling, DNA-binding activity, interaction with p160 coactivators and transdominant negative activity on the wild type receptor, and compared observed mutants? defects with the clinical phenotypes of the patients. We also found a novel pathologic heterozygote mutation that replaces leucine at amino acid 773 of the GR with proline. This mutant demonstrated reduced transactivation activity due to its inability to form a ligand-dependent transactivation surface in its ligand-binding domain and behaved as a dominant negative inhibitor of the normal receptor, thereby producing clinical pathology at the heterozygotic condition. To discover intracellular molecules influencing tissue sensitivity to glucocorticoids, we performed yeast two-hybrid screenings. GR specifically bound one of the orphan nuclear receptors, chicken ovalbumin-upstream promoter-transcription factor II (COUP-TFII). GR and COUP-TFII mutually affected each other's transcriptional activity on the promoters of several genes involved in intermediary metabolism. We also found that the G protein coupled receptor downstream mediator guanine nucleotide-binding protein (G protein) beta and the transforming growth factor beta/bone morphogenetic protein-induced SMAD6 repressor specifically interacted with the GR. Both Gbeta and SMAD6 proteins suppressed GR-induced transactivation of glucocorticoid-responsive promoters. Contrary to dogma, the former protein, with its partner molecule G gamma, co-migrated with the GR into the nucleus in response to glucocorticoids, and was attracted to glucocorticoid response elements (GREs) located in the promoter regions of glucocorticoid-responsive genes. These results indicate that the G protein beta/gamma complexes may suppress the transcriptional activity of the GR by interfering with the GR-associated transcriptosomes on GR-regulated promoters. In contrast, SMAD6 suppressed GR transcriptional activity by attracting histone deacetylases, functioning as a corepressor similarly to other classic molecules, like the nuclear receptor corepressors (NCoR) and the silencing mediator for retinoid and thyroid hormone receptors (SMRT). In addition to the above proteins, we found that the autoimmune regulator protein (AIRE), whose mutations cause the autoimmune polyendocrinopathy candidiasis-ectodermal dystrophy (APECED) syndrome, interacted with the GR and enhanced its transcriptional activity. AIRE has four LXXLL signature motifs through which classic nuclear receptor coactivators interact with ligand-activated receptor molecules. Destruction of these motifs in AIRE disturbed its interaction with the GR and inactivated its enhancing effect on GR transactivation, indicating that AIRE may act as a tissue-specific (thymus) coactivator of GR by using such signature motifs. We are also working on Brx, a Rho type guanine nucleotide exchange factor, which activates the Rho family of small G proteins by converting them from an inactive GDP-bound to an active GTP-bound form. This protein has a nuclear receptor-interacting domain in its C-terminal portion. We have demonstrated that Brx enhanced GR transcriptional activity by activating and closely attracting small G proteins to the GR. Endogenous Brx is necessary for the action of glucocccorticoids in splenic lymphocytes and mediates lysophosphatidic acid (LPA)-induced potentiation of GR transactivation. We are investigating the roles of GRbeta and transcriptional coactivator TRAP220 in regulating tissue sensitivity to glucocorticoids. The former is a splicing variant of the classic receptor GRalpha, while the latter is a component of the huge coactivator protein complex DRIP/TRAP. We developed a stable cell line that over-expresses GFP-GRbeta and obtained TRAP220 KO cells from Dr. R. Roeder?s laboratory. We are examining the impact of their expression/depletion on glucocorticoid-induced transcriptional activity by using regular DNA microarray chips. To elucidate endogenous genes that attract GR to their promoter region, we have developed CpG microarray chips, which include the promoter regions of over 10,000 endogenous genes. We performed chromatin immunoprecipitation assays using antibodies against the GR and will treat the chips with the harvested DNA to discover endogenous promoters that attract GR. Patients with the acquired immunodeficiency syndrome (AIDS), caused by infection with the Human Immunodeficiency Virus type-1 (HIV-1), have several clinical manifestations compatible with increased tissue sensitivity to glucocorticoids. We focused on one of the HIV-1-encoding accessory proteins, Vpr, and demonstrated that this viral polypeptide acts as a coregulator of the GR. We further examined the mechanism of Vpr-induced coactivation of GR transactivation focusing on its interaction with host nuclear receptor coactivators p300/CBP, and addressed the biological significance of Vpr coactivator activity by testing it on the production/secretion of glucocorticoid-responsive interleukin-12 and other gene products. Our findings may explain several manifestations of AIDS, including immunosuppression related to a T-helper 1/T-helper 2 shift, myopathy, muscle weakness/atrophy and obesity-related insulin resistance with metabolic and cardiovascular manifestations.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Molecular Mediators and Regulators of Glucocorticoid Actions
Molecular Mediators and Regulators of Glucocorticoid Actions
Molecular Mediators/Regulators of Glucocorticoid Actions
Molecular Mediators and Regulators of Glucocorticoid Act
海外基金